Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300284 | 0.86 | MMP8 (0.44) | RIPK1MMP8POLBACEALDH1A1 | |
| SCHEMBL17300281 | 0.82 | ALDH1A1 (0.42) | RIPK1MMP8POLBACEALDH1A1 | |
| SCHEMBL3558478 | 0.79 | SMN1; SMN2 (0.47) | RIPK1MMP8POLBACEALDH1A1 | |
| SCHEMBL3558475 | 0.79 | SMN1; SMN2 (0.47) | RIPK1MMP8POLBACEALDH1A1 | |
| SCHEMBL8578336 | 0.79 | MMP8 (0.47) | RIPK1MMP8POLBACEALDH1A1 | |
| SCHEMBL3270164 | 0.78 | PPARA (0.55) | RIPK1MMP8ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL17300285 | 0.77 | MMP8 (0.38) | RIPK1MMP8POLBACEALDH1A1 | |
| SCHEMBL1709337 | 0.77 | RIPK1 (0.75) | RIPK1MMP8ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL3270827 | 0.77 | MMP8 (0.53) | RIPK1MMP8ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL12268231 | 0.76 | RIPK1 (0.46) | RIPK1MMP8ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150342882-A1 | METHODS OF TREATMENT USING CADOTRIL COMPOSITIONS | JOHNSON & JOHNSON CONSUMER INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342882-A1 | METHODS OF TREATMENT USING CADOTRIL COMPOSITIONS | LIPA, DEGS1, ASAH2 | RIPK1 2919/4885MMP8 641/4885POLB 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.